The Federal Circuit recently weighed in on an interference proceeding between the University of California (“UC”) and the Broad Institute over the use of CRISPR-Cas9 technology. The Court affirmed a Patent Trial and Appeal Board (“Board”) decision finding there was no interference-in-fact between UC’s patent application and the claims of twelve patents and one application owned by Institute… Considering the evidence of simultaneous invention, along with evidence regarding the state of the art, inventor statements, and application of similar technologies, the Court concluded the Board’s finding was supported by substantial evidence.
The post Federal Circuit Affirms Board: No Interference-in-Fact for CRISPR-Cas9 Technology appeared first on IPWatchdog.com | Patents & Patent Law.
Recent Posts
- Foreign Price Controls: A Risk to U.S. Medical Innovation and Patient Access
- Other Barks & Bites for Friday, July 11: EGC Affirms Annulment of Rubik’s Cube Marks; Sysco Trade Secret Case Dismissal Affirmed by Fourth Circuit; and EU Advocate General Finds Member States Can Impose Measures to Protect News Content on Meta Platforms
- EU Publishes Code of Practice as Deadline for AI Act’s Provisions on General-Purpose AI Models Nears
- Will the Federal Circuit Finally Follow Supreme Court Holdings on the Unavailability of the Laches Defense?
- CAFC Upholds Win for Janssen on Patent for Antipsychotic Med Dosing Regimen